Association of cytokines with quality of life among breast cancer survivors: A randomized pilot study exploring the effect of Tai Chi Chuan

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e20556-e20556
Author(s):  
T. V. Darling ◽  
K. M. Mustian ◽  
C. E. Heckler ◽  
L. J. Peppone ◽  
M. C. Janelsins ◽  
...  

e20556 Background: While advances in cancer treatment can increase breast cancer (BC) survival, cancer treatment side effects can decrease quality of life (QOL). Cancer cardiotoxicity is a major side effect of chemotherapy and radiotherapy that leads to cardiovascular disease (CVD). The combined burden of cancer and cancer cardiotoxicity drastically affects QOL. Cytokine-mediated inflammatory profiles are dysregulated by cancer treatments and are implicated in the pathogenesis of CVD. Tai Chi Chuan (TCC), an exercise mode with an energy expenditure equivalent to brisk walking, has been shown to improve cardiovascular function and QOL among BC survivors. The purpose of this pilot study was to explore how TCC affects cytokines and how cytokine changes are related to QOL changes among BC survivors. Methods: This pilot study compared the effects of 12 weeks (3, 60 min. sessions/week) of TCC with support therapy on IL-2 and IL-8 and on QOL among 21 BC survivors (mean age=51; range 33–78). Cytokine responses were obtained via serum ELISA and QOL were assessed via the FACIT measurement system pre- and post-intervention. Results: Mean levels of IL-2 decreased in the TCC group (CS=-8.82) but increased in the control group (CS=4.60). Mean levels of IL-8 increased in the TCC group (CS=0.32) but decreased in the control group (CS=-3.82). ANCOVA, controlling for baseline, revealed no treatment effect for IL-2 but there was a statistical trend suggesting a possible treatment effect and baseline interaction for IL-8 (p=0.1). Bivariate analyses revealed a negative association between overall QOL and IL-8 (p=0.07), functional QOL (e.g. ability to work) and IL-8 (p=0.03), as well as physical QOL (e.g. energy level) and IL-8 (p=0.01) in the TCC group. Correlations also showed a negative association between overall QOL and IL-2 (p=0.05) and between functional QOL and IL-2 (p=0.005) among the control group. Conclusions: These findings suggest that TCC-induced changes in cytokines may be associated with changes in QOL, specifically in the physical and functional domains. Future research is needed to verify these pilot study findings and should focus on cardiotoxic effects associated with physical and functional QOL. NCI grant 1R25-CA102618 and Sally Schindel Cone. No significant financial relationships to disclose.

2010 ◽  
Vol 42 ◽  
pp. 162
Author(s):  
Lisa K. Sprod ◽  
Oxana G. Palesh ◽  
Luke J. Peppone ◽  
Michelle C. Janelsins-Benton ◽  
Charles E. Heckler ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Wilfried Tröger ◽  
Zdravko Ždrale ◽  
Nevena Tišma ◽  
Miodrag Matijašević

Background. Breast cancer patients receiving adjuvant chemotherapy often experience a loss of quality of life. Moreover chemotherapy may induce neutropenia. Patients report a better quality of life when additionally treated with mistletoe products during chemotherapy.Methods. In this prospective randomized open-label pilot study 95 patients were randomized into three groups. All patients were treated with an adjuvant chemotherapy. The primary objective of the study was quality of life, the secondary objective was neutropenia. Here we report the comparison of HxA (n= 34) versus untreated control (n= 31).Results. In the explorative analysis ten of 15 scores of the EORTC QLQ-C30 showed a better quality of life in the HxA group compared to the control group (P<0.001toP=0.038in Dunnett-T3 test). The difference was clinically relevant (difference of at least 5 points, range 5.4–12.2) in eight of the ten scores. Neutropenia occurred in 7/34 HxA patients and in 8/31 control patients (P= 0.628).Conclusions. This pilot study showed an improvement of quality of life by treating breast cancer patients with HxA additionally to CAF. Although the open design may be a limitation, the findings show the feasibility of a confirmatory study using the methods described here.


2004 ◽  
Vol 12 (12) ◽  
pp. 871-876 ◽  
Author(s):  
Karen M. Mustian ◽  
Jeffrey A. Katula ◽  
Diane L. Gill ◽  
Joseph A. Roscoe ◽  
David Lang ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-15 ◽  
Author(s):  
Yuanqing Pan ◽  
Kehu Yang ◽  
Xiue Shi ◽  
Haiqian Liang ◽  
Fengwa Zhang ◽  
...  

Objective. Tai Chi Chuan (TCC) is a form of aerobic exercise that may be an effective therapy for improving psychosomatic capacity among breast cancer survivors. This meta-analysis analyzed the available randomized controlled trials (RCTs) on the effects of TCC in relieving treatment-related side effects and quality of life in women with breast cancer.Methods. RCTs were searched in PubMed, Embase, Web of Science, and Cochrane Library through April 2014. Data were analyzed on pathology (pain, interleukin-6, and insulin-like growth factor 1), physical capacity (handgrip, limb physical fitness, and BMI), and well-being (physical, social, emotional, and general quality of life).Results. Nine RCTs, including a total of 322 breast cancer patients, were examined. Compared with control therapies, the pooled results suggested that TCC showed significant effects in improving handgrip dynamometer strength, limb elbow flexion (elbow extension, abduction, and horizontal adduction). No significant differences were observed in pain, interleukin-6, insulin-like growth factor, BMI, physical well-being, social or emotional well-being, or general health-related quality of life.Conclusion. The short-term effects of TCC may have potential benefits in upper limb functional mobility in patients with breast cancer. Additional randomized controlled trials with longer follow-up are needed to provide more reliable evidence.


2008 ◽  
Vol 36 (03) ◽  
pp. 459-472 ◽  
Author(s):  
Byeongsang Oh ◽  
Phyllis Butow ◽  
Barbara Mullan ◽  
Stephen Clarke

Quality of life (QOL) of cancer patients is often diminished due to the side effects of treatment and symptoms of the disease itself. Medical Qigong (coordination of gentle exercise and relaxation through meditation and breathing exercise based on Chinese medicine theory of energy channels) may be an effective therapy for improving QOL, symptoms and side effects, and longevity of cancer patients. In this pilot study, the feasibility, acceptability, and impact of Medical Qigong (MQ) were evaluated on outcomes in cancer patients. Thirty patients diagnosed with heterogeneous cancers, were randomly assigned to two groups: a control group that received usual medical care and an intervention group who participated in a MQ program for 8 weeks in addition to receiving usual medical care. Randomization was stratified by completion of cancer treatment ( n = 14) or under chemotherapy ( n = 16). Patients completed measures before and after the program. Quality of life and symptoms were measured by the EORTC QLQ-C 30 and progress of disease by the inflammation biomarker (CRP: c-reactive protein) via a blood test was assessed. The MQ intervention group reported clinically significant improved global QOL scores pre- and post-intervention. The MQ intervention also reduced the symptoms of side effects of cancer treatment and inflammation biomarker (CRP) compare to the control group. Due to the small sample size, however, the results were not statistically significant between treatment and the control groups. Data from the pilot study suggest that MQ with usual medical treatment can enhance the QOL of cancer patients and reduce inflammation. This study needs a further investigation with a larger sample size.


2011 ◽  
Vol 6 (2) ◽  
pp. 146-154 ◽  
Author(s):  
Lisa K. Sprod ◽  
Michelle C. Janelsins ◽  
Oxana G. Palesh ◽  
Jennifer K. Carroll ◽  
Charles E. Heckler ◽  
...  

2018 ◽  
Vol 4 ◽  
pp. 3-13
Author(s):  
Yuriy Dumanskiy ◽  
Oleksandr Bondar ◽  
Oleksandr Tkachenko ◽  
Evhenii Stoliachuk ◽  
Vasilii Ermakov

In recent years, breast cancer (BC) is the most common cancer pathology and the most common cause of disability among women in developed countries. Finding the most effective ways of interaction between the patient and the doctor creates the preconditions for the necessary analysis of the treatment process from an objective and subjective point of view. Therefore, an important indicator to be taken into account is the quality of life of a patient. To compare the indicators of a comprehensive assessment of the quality of life of patients to the adverse locally advanced forms (LA) of breast cancer before and after systemic intravenous polychemotherapy (SPCTx) and selective endolymphatic polychemotherapy (ELPCTx) in neoadjuvant mode. The study was conducted on the basis of a random analysis of outpatient cards from 112 patients with LA BC T4A-DN0-3M0 who received a comprehensive antitumor treatment on the basis of the Donetsk regional antitumor center and the University Clinic of the Odessa National Medical University from 2000 to 2017, which was proposed a questionnaire at various stages of preoperative treatment. The first (control) group consisted of 65 patients (58 %) with inoperable forms of LA BC, which was performed in neoadjuvant mode by SPCTx. The second (study group) included 47 patients (42 %) with inoperable forms of LA BC, which was performed as a neoadjuvant course ELPCTx. According to the integral indicators of quality of life and quality of health between patients in the control and study groups, there was no statistically significant difference. In a detailed analysis of the indicators of symptomatic scales, the difference between the groups did not exceed the critical. Based on the results of a study conducted among patients receiving endolymphatic chemotherapy in a neoadjuvant mode, the subjective evaluations of treatment in absolute numbers have better reference values without statistical superiority. The study of the integrative indicator of quality of life and its discrete elements is an ergonomic and economical means of heuristic assessment of the health of patients in order to further develop more rational and convenient ways of solving urgent issues of modern oncology by increasing compliance and finding a compromise between the physician and the patient.


2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Mads G. Jørgensen ◽  
Navid M. Toyserkani ◽  
Frederik G. Hansen ◽  
Anette Bygum ◽  
Jens A. Sørensen

AbstractThe impact of breast cancer-related lymphedema (BCRL) on long-term quality of life is unknown. The aim of this study was to investigate the impact of BCRL on health-related quality of life (HRQoL) up to 10 years after breast cancer treatment. This regional population-based study enrolled patients treated for breast cancer with axillary lymph node dissection between January 1st 2007 and December 31th 2017. Follow up and assessments of the included patients were conducted between January 2019 and May 2020. The study outcome was HRQoL, evaluated with the Lymphedema Functioning, Disability and Health Questionnaire, the Disabilities of the Arm, Shoulder and Hand Questionnaire and the Short Form (36) Health Survey Questionnaire. Multivariate linear logistic regression models adjusted for confounders provided mean score differences (MDs) with 95% confidence intervals in each HRQoL scale and item. This study enrolled 244 patients with BCRL and 823 patients without BCRL. Patients with BCRL had significantly poorer HRQoL than patients without BCRL in 16 out of 18 HRQoL subscales, for example, in physical function (MDs 27, 95%CI: 24; 30), mental health (MDs 24, 95%CI: 21; 27) and social role functioning (MDs 20, 95%CI: 17; 23). Age, BMI, BCRL severity, hand and dominant arm affection had only minor impact on HRQoL (MDs < 5), suggesting a high degree of inter-individual variation in coping with lymphedema. This study showed that BCRL is associated with long-term impairments in HRQoL, especially affecting the physical and psychosocial domains. Surprisingly, BCRL diagnosis rather than clinical severity drove the largest impairments in HRQoL.


Sign in / Sign up

Export Citation Format

Share Document